Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability and immunogenicity of Baxter vs GSK H1N1 vaccines in children
2009-014719-11Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in influenza A virus infection (H1N1) and influenza (2 arms), sponsored by University of Oxford. Primary endpoint: Primary immunogenicity endpoint. Started Sep 2009; status: completed.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
influenza A virus infection (H1N1)influenza
Beyond the preview
Go deeper on 2009-014719-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014719-11.